CC
LUCD icon

Covalis Capital’s Lucid Diagnostics LUCD Stock Holding History

Covalis Capital’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-134,532
Closed -$722K – 86
2021
Q4 		$722K Buy
+134,532
New +$1.09M 0.26% 46

Other funds holding LUCD

LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Covalis Capital's LUCD Position: Q1 2022 in Review

Covalis Capital sold out of Lucid Diagnostics (LUCD) in Q1 2022, closing a stake of 134,532 shares — an estimated $722K sold.

Covalis Capital first reported a position in LUCD in Q4 2021 and held it in 1 quarter. The position peaked at $722K in Q4 2021. 32 funds tracked by Wall St. Rank hold LUCD as of Q1 2022.

  • Covalis Capital reported no remaining Lucid Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Covalis Capital sold 134,532 Lucid Diagnostics shares in Q1 2022, an estimated $722K.
  • Covalis Capital first reported a position in Lucid Diagnostics in Q4 2021 and held it in 1 quarter.
  • Covalis Capital's Lucid Diagnostics position peaked at $722K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2022.

Based on Covalis Capital's 13F filing for Q1 2022, filed 16 May 2022.